RxDoctor Payments Data

Steven Cohn, MD

Cardiovascular Disease · Tamarac, FLNPI 1174747810

Payments from drug & device makers

$1,394in general payments, 2019–2025

Across 71 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$334
  • Novo Nordisk$310
  • Lilly USA, LLC$182
  • Johnson & Johnson$132
  • E.r. Squibb & Sons, L.L.C.$119
  • GSK$78
  • plus $239 from 7 others

What the payments were for

  • Food & beverage$1,37899%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer17$334
Novo Nordisk13$310
Lilly USA, LLC11$182
Johnson & Johnson7$132
E.r. Squibb & Sons, L.L.C.6$119
GSK4$78
Amgen3$52
Boehringer Ingelheim2$50
Novartis3$50
Abbott1$33
AstraZeneca2$30
Amarin Pharma, Inc.1$14
Bardy Diagnostics, Inc.1$10

How this compares

$1,394 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$55,832
Medicare patients
138
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$175,187
EliquisApixaban98$120,657
JardianceEmpagliflozin82$117,246
XareltoRivaroxaban68$75,842
MounjaroTirzepatide30$55,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$54,181
JanuviaSitagliptin Phosphate20$34,095
TradjentaLinagliptin27$33,970
FarxigaDapagliflozin Propanediol27$27,195
EntrestoSacubitril/Valsartan14$19,186
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$18,422
MyrbetriqMirabegron12$13,361
TrulicityDulaglutide11$10,681
Atrovent HfaIpratropium Bromide19$9,900
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$8,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$310$175,187102 claims
Boehringer IngelheimJardiance, Tradjenta$50$151,216109 claims
PfizerEliquis$334$120,65798 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$78$77,34177 claims
Johnson & JohnsonXarelto$132$75,84268 claims
Lilly USA, LLCMounjaro, Trulicity$182$66,21941 claims
AstraZenecaFarxiga, Symbicort$30$32,43642 claims
NovartisEntresto$50$19,18614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →